| Literature DB >> 27039104 |
James A Heslop1, Cliff Rowe2, Joanne Walsh1, Rowena Sison-Young1, Roz Jenkins1, Laleh Kamalian1, Richard Kia1, David Hay1, Robert P Jones3, Hassan Z Malik3, Stephen Fenwick3, Amy E Chadwick1, John Mills4, Neil R Kitteringham1, Chris E P Goldring5, B Kevin Park1.
Abstract
The application of primary human hepatocytes following isolation from human tissue is well accepted to be compromised by the process of dedifferentiation. This phenomenon reduces many unique hepatocyte functions, limiting their use in drug disposition and toxicity assessment. The aetiology of dedifferentiation has not been well defined, and further understanding of the process would allow the development of novel strategies for sustaining the hepatocyte phenotype in culture or for improving protocols for maturation of hepatocytes generated from stem cells. We have therefore carried out the first proteomic comparison of primary human hepatocyte differentiation. Cells were cultured for 0, 24, 72 and 168 h as a monolayer in order to permit unrestricted hepatocyte dedifferentiation, so as to reveal the causative signalling pathways and factors in this process, by pathway analysis. A total of 3430 proteins were identified with a false detection rate of <1 %, of which 1117 were quantified at every time point. Increasing numbers of significantly differentially expressed proteins compared with the freshly isolated cells were observed at 24 h (40 proteins), 72 h (118 proteins) and 168 h (272 proteins) (p < 0.05). In particular, cytochromes P450 and mitochondrial proteins underwent major changes, confirmed by functional studies and investigated by pathway analysis. We report the key factors and pathways which underlie the loss of hepatic phenotype in vitro, particularly those driving the large-scale and selective remodelling of the mitochondrial and metabolic proteomes. In summary, these findings expand the current understanding of dedifferentiation should facilitate further development of simple and complex hepatic culture systems.Entities:
Keywords: Cytochrome P450s; Donor-variation; Human hepatocytes; Mass spectrometry; Mitochondria; iTRAQ
Mesh:
Substances:
Year: 2016 PMID: 27039104 PMCID: PMC5225178 DOI: 10.1007/s00204-016-1694-y
Source DB: PubMed Journal: Arch Toxicol ISSN: 0340-5761 Impact factor: 5.153
Fig. 1Morphological and statistical analysis a morphological changes in primary human hepatocytes over 168 h in monolayer collagen-I-coated plate culture. Scale bar represents 10 µm; b volcano plot analysis of the iTRAQ detected proteins log fold change versus p value at 24, 72 and 168 h. Blue significantly altered proteins (n = 5; p ≤ 0.05) and red significantly altered after multiple testing correction (n = 5; Benjamini–Hochberg ≤0.05) c hierarchal clustering analysis showing the relationship between donors and time points (n = 5); d heatmap of each donor’s proteome during dedifferentiation relative to the freshly isolated sample. Red indicates down-regulation, yellow up-regulation. The intensity of colour reflects the degree of change
Fig. 2Pathway analysis of dedifferentiation a biological functions associated with the DEPs according to Z-activation score. If score 2 ≥ Z-score ≤ −2, the function is predicted to be activated or inhibited, respectively. Red up-regulated, green down-regulated. Intensity of colour correlates with greater Z-activation score b canonical pathways during dedifferentiation. Results displayed—Log (p values), pathway included if p < 0.05 at any of the assessed time points. Colour Intensity corresponds to the significance value; c upstream regulators predicted to be either activated or inhibited by Z-activation score (2 ≥ Z-score ≤ −2). Red activated, green inhibited, in order of significance
Fig. 3Mitochondrial changes during dedifferentiation. a Log2 fold change of mitochondrial proteins. Red up-regulated, green down-regulated. Intensity of colour log2 fold change. Bold proteins differentially expressed at 168 h (p < 0.05); b (i) oxidative phosphorylation and (ii) glycolysis parameters as percentages of maximal oxygen consumption rates and extracellular acidification rate, respectively; relative fold change of (iii) oxidative phosphorylation and (iv) glycolysis parameters. (*) p < 0.05 two-tailed paired t test; c ATP levels at 24 (filled diamond) and 168 h (filled square) following rotenone treatment. Results: percentage of control, (*) p < 0.05 two-tailed paired t test and (†) p < 0.05 Wilcoxon signed rank test (n = 5)
Fig. 4Loss of hepatic metabolic phenotype. a ADME phases I, II and III enzyme heatmap. Red up-regulated, green down-regulated. Intensity of colour relative fold change. Data derived from n ≥ 3 donors unless stated (†) n = 2 or (‡) n = 1; b CYP450 s over 168 h (n = 5); error bars SD; one-way ANOVA: (*) p < 0.05, (#) p < 0.01); c western blots for CYP450 s and β-actin; d metabolic function of CYP3A (testosterone) and CYP2D6 (dextromethorphan) and detection of respective metabolites (6β-OH-testosterone and dextrorphan) detected by LC–MS–MS (n = 3; error bars SD); e ADME transporters protein expression during dedifferentiation. Error bars SD,* significant p < 0.05 by one-way ANOVA